Dehydration, Rehydration, and Impact on Physiology (DRIP)

Texas Tech University

Status: Enrolling

Conditions: Aging

Treatments: Behavioral: Hydration-Dehydration-Rehydration Protocol (HDR)

Study type: Interventional

Funder types: Other

Identifiers

NCT07084675

IRB2025-288

Details and patient eligibility

About

Our goal is to determine whether hydration status influences inflammation, and overall physiological performance in adults aged 45-65.

Aim 1: The effects of 4-day mild dehydration followed by 4-day rehydration (defined as approximately 2-3% body mass loss) on H2O2, upstream inflammatory signal (NFkB), mitochondrial fragmentation, and autophagy in circulating PBMCs.

Aim 2: The effects of 4-day mild dehydration followed by 4-day rehydration (defined as approximately 2-3% body mass loss) on fasting glucose, sleep performance, and strength performance.

Participant will:

complete a 4-day hydration protocol, followed by a 4-day dehydration protocol, and then a 4-day rehydration protocol.

attend five laboratory visits for testing: Day 1: Informed consent and familiarization Day 2: Pre-hydration testing (before the 4-day hydration protocol) Day 3: Pre-dehydration testing (before the dehyration protocol) Day 4: Post-dehydration testing (after the dehydration protocol) Day 5: Post-rehydration testing (after the rehydration protocol)

Enrollment: 15 estimated patients

Sex: All

Ages: 45 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Apparently Healthy
• BMI < 30 kg/m2
• Body weight is at least 110 lbs

Exclusion criteria

• Currently pregnant
• Have Type 1 Diabetes or Type 2 Diabetes
• Have chronic kidney disease or a history of kidney stones
• Have hypertension
• Take medications that can cause fluid retention, such as corticosteroids, chronic use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapies (e.g., estrogen, androgens or anabolic steroids), Antihypertensives, Psychiatric Medications (e.g., Lithium), Vasodilators
• Take medications that reduce fluid retention: diuretics, and RAAS Inhibitors (e.g., ACE inhibitors and ARBs)

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Hydration-Dehydration-Rehydration (HDR) Protocol Arm

Experimental group

Description:

Participants in this arm complete the HDR Protocol over 12 days and attend five lab visits.

Treatment:

Behavioral: Hydration-Dehydration-Rehydration Protocol (HDR)